Swiss biotech CFO meeting
Monday, October 19, 2026, 9:30 - 17:00
Stadttheater, Frohburgstrasse 1, 4600 Olten
(4 min. walking distance from the Olten train station)
We are delighted to invite you to our annual informal peer-to-peer Swiss biotech CFO meeting.
In this relaxed and interactive setting, you are encouraged to openly share and discuss your unique requirements as a CFO/finance specialist in the biotech sector.
We exchange ideas, share valuable experiences, and collaboratively shape the ideal framework conditions to raise financial resources and enable partnering for biotechs.
Your participation and input are vital for the event’s success. We warmly welcome you to share your ideas to help shape our program further as you register below.
Program morning session
The fourth Swiss Biotech CFO Meeting will open with a timely focus on how AI is reshaping fundraising, partnering, and finance.
09:30 – 10:00
Welcome coffee
10:00 – 10:20
Opening note
- Maximilien Murone, Liaison Basel Northwestern Switzerland, Swiss Biotech Association
- Michael Altorfer, CEO, Swiss Biotech Association
10:20 – 11:00
Keynote lectures
The Execution Blind Spot:
Why biotech measures science, capital and risk, but not whether the organisation can deliver
Jason Beckwith, Founder Talent Science, SVP BioTalent & University of Leeds
Preparing the ground to implement AI tools in your organisation
Dirk Jochen Ziegler, Founder, InVeVol
11:00 – 11:45
AI tools: From pilot to embedded solution
Panel discussion moderated by Philipp Gutzwiller
Adesh Kaul, CFO, Basilea Pharmaceutica
Laura Stienen, Director, AI & Data and AI Strategy Lead, Deloitte
Charlie Smelt, Head of AI Strategy, Roche
11:45 – 12:30
AI tools for due diligence
Panel discussion moderated by Maximilien Murone
Matti Kesti, CEO, Revonode
Dragana Avramovic, Founder, DragonIT/FIDAI
Nicolas Bornitz, Director, M&A Transaction Services, Deloitte
Florin Muraru, Founder, Regsynapse
12:30 – 14:00
Networking lunch
Preliminary program afternoon session
More program details and speakers will be announced in due course.
14:00 – 14:15
Swiss Biotech Association’s contribution to the Swiss biotech community
14:15 – 16:00
Selected cases and financing rounds from the Swiss biotech ecosystem
Lars Spenger, CFO, Memo Therapeutics: Memo Therapeutics’ acquisition by Ipsen
Rajwinder Lehal, CEO, Cellestia Biotech: Unlocking pipeline value through spin-offs – the Cellestia Biotech example
Stephan Emmerth, Director Therapeutic Innovation & BaseLaunch, Basel Area Business & Innovation: Title to be announced
16:00 – 17:00
Networking apero
Register before October 9
